Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 736 to 750 of 8314 results

  1. Breast cancer

    All NICE products on breast cancer. Includes any guidance, advice and quality standards.

    Topic page

  2. Skin infections

    All NICE products on skin infections. Includes any guidance and advice.

    Topic page

  3. Artificial intelligence

    All NICE products on artificial intelligence. Includes any advice.

    Topic page

  4. Serious eye disorders (QS180)

    This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    12 February 2019
    View quality statements

    Sections for QS180

  5. Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

    In development Reference number: GID-TA11232 Expected publication date:  28 January 2026

    Technology appraisal guidance
    In development

  6. Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]

    In development Reference number: GID-TA11498 Expected publication date:  28 January 2026

    Technology appraisal guidance
    In development

  7. Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]

    In development Reference number: GID-TA11504 Expected publication date:  28 January 2026

    Technology appraisal guidance
    In development

  8. Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]

    In development Reference number: GID-TA11298 Expected publication date:  29 January 2026

    Technology appraisal guidance
    In development

  9. Balloon cryoablation for Barrett's oesophagus

    In development Reference number: GID-IPG10413 Expected publication date:  29 January 2026

    Interventional procedures guidance
    In development

  10. Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) (TA867)

    NICE is unable to make a recommendation on mitapivat (Pyrukynd) for treating pyruvate kinase deficiency in adults because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    16 February 2023

    Sections for TA867

  11. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) (TA879)

    NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after a previous anti-HER2-based regimen in adults. This is because Daiichi Sankyo UK did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    6 April 2023

    Sections for TA879

  12. Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) (TA910)

    NICE is unable to make a recommendation on semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    13 July 2023

    Sections for TA910

  13. Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal) (TA899)

    NICE is unable to make a recommendation on esketamine (Spravato) for treating major depressive disorder in adults at imminent risk of suicide because Janssen did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    6 June 2023

    Sections for TA899

  14. Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)

    NICE is unable to make a recommendation on cemiplimab (Libtayo) for treating recurrent or metastatic cervical cancer in adults because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    20 June 2023

    Sections for TA901

  15. Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA889)

    NICE is unable to make a recommendation on ciltacabtagene autoleucel (Carvykti) for treating relapsed or refractory multiple myeloma in adults. This is because Janssen withdrew its evidence submission for the appraisal. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    17 May 2023

    Sections for TA889